# US 2026/0069619 A1 · Treatment of Dry Eye Disease Using Mitochondrially Targeted Antioxidants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0069619 A1
- Document ID: US20260069619A1
- Status: Published application
- Kind: A1
- Application number: 18/872,454
- Filed: 2022-06-06
- Published: 2026-03-12
- Earliest claimed: 2022-06-06
- Assignees: Mitotech SA
- Applicants: Mitotech S.A.
- Inventors: Maxim SKULACHEV; Anton PETROV
- Web page: https://patentgrep.com/patent/US20260069619A1

## CPC

- A61K 31/66: Phosphorus compounds
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 33/42: Phosphorus; Compounds thereof
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Formulations and methods of using mitochondrially targeted antioxidants (SkQ) to improve dry eye conditions in subjects having a tear production of ≥7 mm measured by a Schirmer's test are provided. The methods provide benefits to the population-specific group of subjects but do not provide benefits to subjects having a tear production of <7 mm, as measured by a Schirmer's test.

## Claims

### Claim 1

A formulation comprising a compound of Formula I:
wherein A is a quinone antioxidant having the following structure:
and/or a reduced quinole form thereof; wherein m is an integer from 1 to 3, and each Y is independently selected from the group consisting of C1-6 alkyl and C1-6 alkoxy (—O—C1-6);
wherein L is a linker group, comprising:
a) a straight or branched hydrocarbon chain which can optionally be substituted by one or more substituents and which can optionally contain one or more double and/or triple bonds; and/or
b) a natural isoprene chain;
n is an integer from 1 to 40;
B is a targeting group comprising Sk+Z−; wherein Sk+ is a lipophilic cation, and Z− is a pharmaceutically acceptable anion;
wherein the formulation comprises SkQ at a concentration of ≥0.5 μg/mL; and
wherein the formulation is suitable to aid in treating a subject having a dry eye condition. the subject's eye having a tear production of ≥7 mm measured by a Schirmer's test, and providing an improvement in one or more signs and/or one or more symptoms of dry eye disease.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the SkQ comprises SkQ1 shown below, in its reduced or oxidized form:
or a combination thereof.

### Claim 3

The formulation of any of the preceding claims, wherein the formulation is an eye-drop or eye-gel formulation and is suitable to be applied topically to the eye and/or to one or more adnexa of the eye.

### Claim 4

The formulation of any of the preceding claims, wherein the one or more signs of dry eye disease comprise a grade of corneal staining of >0 in the whole cornea or a portion thereof.

### Claim 5

The formulation of any of the preceding claims, wherein the one or more symptoms of dry eye disease comprise an index of blurred vision ≥1 or poor vision ≥1, and/or a reduced visual acuity of the eye.

### Claim 6

The formulation of any of the preceding claims, wherein the formulation is suitable to be applied topically to the eye, and the formulation is suitable to contact one or more adnexa of the eye via a spreading of the formulation on the surface of the eye, an eye blink, an eye movement, or a combination thereof.

### Claim 7

The formulation of any of the preceding claims, wherein the one or more or said signs of dry eye disease comprise a grade of corneal staining >0 in the whole cornea or a portion thereof, and the one or more symptoms of dry eye disease comprise a reduced visual acuity of the eye.

### Claim 8

The formulation of any of the preceding claims, wherein the formulation is suitable for use in a method comprising the steps of:
(a) applying a fluorescein stain to the eye;
(b) measuring a grade of central corneal fluorescein staining;
(c) repeatedly treating the eye with the formulation after steps (a) and (b);
thereby providing a reduction or a complete clearing in the grade of central corneal fluorescein staining of the eye.

### Claim 9 (depends on 8)

The formulation of claim 8, wherein the grade of central corneal fluorescein staining is initially >0 and finally=0.

### Claim 10

The formulation of any of the preceding claims, wherein the subject has a reported index of blurred vision of ≥1 or poor vision of ≥1, and/or a reduced visual acuity of the eye before a treatment with the formulation, and wherein the formulation is suitable to provide an improvement in the visual acuity of the eye after the treatment.

### Claim 11 (depends on 10)

The formulation of claim 10, wherein the improvement in visual acuity is an improvement in a best corrected visual acuity (BCVA) of the eye, and wherein the improvement in BCVA is an improvement of BCVA of about ≥0.3.

### Claim 12 (depends on 11)

The formulation of claim 11, wherein the BCVA is measured as a logarithm of the minimum angle of resolution chart measurement.

### Claim 13 (depends on 11, 12)

The formulation of claim 11 or 12, wherein the improvement in BCVA further comprises an improvement in the index of blurred vision and/or the index of poor vision.

### Claim 14 (depends on 10, 11, 12, 13)

The formulation of any of claims 10-13, wherein the reported index of blurred vision is a rating on a scale range of 0-4 by the subject of an experience of blurred vision during the week before a treatment with the formulation; wherein 0=none of the time, 1=some of the time, 2=half of the time, 3=most of the time, and 4=all of the time.

### Claim 15 (depends on 10, 11, 12, 13)

The formulation of any of claims 10-13, wherein the reported index of poor vision is a rating on a scale range 0-4 by the subject of an experience of poor vision during the week before a treatment of the subject; wherein 0=none of the time, 1=some of the time, 2=half of the time, 3=most of the time, and 4=all of the time.

### Claim 16

The formulation of any of the preceding claims, wherein the one or more signs and/or the one or more symptoms of dry eye disease comprise one or more of the following: tear production in the eye of ≥7 mm by a Schirmer's test, a grade of central corneal fluorescein staining of >0, a total fluorescein corneal staining score of ≥2, a total lissamine green conjunctival staining score of ≥2, corneal sensitivity, conjunctival redness, lid margin redness, damage to the cornea, subject eye grittiness, eye itching or discomfort, reduced visual acuity, and subject reported blurred vision, poor vision, eye pain, eye photosensitivity, or eye pain.

### Claim 17

The formulation of any of the preceding claims, wherein the formulation is suitable for treating the subject's eye over a period of about 14 days to about 90 days.

### Claim 18

The formulation of any of the preceding claims, wherein the one or more signs and/or one or more symptoms of dry eye disease are associated with a condition comprising one or more of the following: eye strain due to reading, driving at night, watching a display screen, or contact lens wear, exposure to an environmental eye irritant, hormone replacement therapy, exposure to the wind or dry air, allergies, eye surgery, a side effect of a medication, thyroid disease, disease of aging, an infection, exposure keratitis, vitamin deficiency, Sjogren's syndrome, and a condition associated with keratoconjunctivitis sicca, keratitis sicca, or an immune system disorder.

### Claim 19 (depends on 18)

The formulation of claim 18, wherein the infection is a bacterial infection, fungal infection, or viral infection.

### Claim 20

The formulation of any of the preceding claims, wherein the SkQ comprises one or more compounds, in oxidized or reduced form, or a mixture thereof, selected from the group consisting of the following compounds:

### Claim 21

The formulation of any of the preceding claims, wherein the pharmaceutically acceptable anion Z− comprises acetate, bromide, camsylate, chloride, formate, fumarate, maleate, mesylate, nitrate, oxalate, phosphate, dihydrogen phosphate dodecahydrate, dihydrogen phosphate dihydrate, sulfate, tartrate, thiocyanate, tosylate, adipate, caprate, caproate, caprylate, dodecylsulfate, glutarate, laurate, oleate, palmitate, sebacate, stearate, undecylenate, or a combination thereof.

### Claim 22

The formulation of any of the preceding claims, wherein the SkQ optionally comprises a hydrate comprising one or more water molecules associated via a hydrogen bonding and/or an ionic bonding to the A, L, Sk+, and/or to Z−.

### Claim 23

The formulation of any of the preceding claims, wherein the formulation is suitable for treating a subject at a dose of at least one drop or at least about 0.05 mL of the formulation to the eye and/or to one or more adnexa of the eye at least once every 24 hours.

### Claim 24

The formulation of any of the preceding claims, wherein the formulation comprises one or more of the following: benzalkonium chloride, hypromellose, sodium chloride, sodium dihydrogen phosphate dihydrate, sodium dihydrogen phosphate dodecahydrate, and water.

### Claim 25

The formulation of any of the preceding claims, wherein the Schirmer's test score is an unanesthetized Schirmer's test score.

### Claim 26

The formulation of any of the preceding claims, wherein the one or more symptoms of dry eye disease comprise one or more symptoms reportable by the subject.

### Claim 27

The formulation of any of the preceding claims, wherein the one or more signs and/or the one or more symptoms of dry eye disease arise from a progressive dry eye disease for longer than about 2 months.

### Claim 28 (depends on 27)

The formulation of claim 27, wherein a damage to the central cornea is indicated by a grade of central corneal fluorescein staining of ≥1.

### Claim 29

The formulation of any of the preceding claims, wherein the formulation comprises SkQ at a concentration of ≥1 μg/mL.

### Claim 30

A kit for treating one or more signs and/or one or more symptoms of dry eye disease, the kit comprising:
a dispensing container comprising an eye-drop or eye-gel formulation comprising SkQ at a concentration of ≥0.5 μg/mL; and
instructions for use.

### Claim 31 (depends on 28)

The kit of claim 28, wherein the eye-drop or eye-gel formulation comprises SkQ at a concentration of ≥1 μg/mL.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

Use of the formulation of any of claims 1-29 or the kit of claim 30 or 31 to treat or prevent dry eye syndrome in a subject in need thereof.

### Claim 33 (depends on 32)

The use of claim 32, wherein the subject's eye has a tear production of ≥7 mm measured by a Schirmer's test,
